BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 25, 2010
 |  BioCentury  |  Product Development

Lexicon's SGLT Two-Step

There are at least eight sodium-glucose transporter 2 inhibitors in development for Type II diabetes, including three in Phase III testing, but Lexicon Pharmaceuticals Inc. thinks its LX4211 may offer some important advantages. The compound was designed based on the hypothesis that complementing potent inhibition of SGLT2 in the kidneys with limited inhibition of SGLT1 in the gut would provide better glycemic control than targeting SGLT2 alone without causing gastrointestinal problems.

Phase II data reported last week provided proof of concept and more, as LX4211 also demonstrated the unexpected benefit of reducing triglycerides.

The double-blind, North American Phase II trial compared 150 and 300 mg of oral LX4211 given once daily vs. placebo for 28 days in 36 patients. Both doses of LX4211 met the primary endpoint of significantly increasing 24-hour urinary glucose excretion from baseline to week four vs. placebo (p=0.001 and p<0.001, respectively).

The 150 and 300...

Read the full 745 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >